Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

Inclusion Criteria: Subjects will be eligible for study entry if they: * are at least 18 years old * have a form of primary immunodeficiency (PID) as described by Rosen et al, 1999 16 manifesting as agammaglobulinemia (X-linked) or hypogamma-globulinemia (common variable immunodeficiency), requiring immunoglobulin replacement therapy * have had regular treatment for at least three months with either intravenous immunoglobulin preparations or immunoglobulin preparations for intramuscular use given subcutaneously * have serum IgG levels greater than or equal to 5 g/L as determined by the local laboratory at screening * if female of childbearing potential, agree to employ adequate birth control measures during the study * have given written informed consent Exclusion Criteria: Subjects will not be eligible for study entry if they: * had severe adverse reactions to treatment with immunoglobulin preparations during the last three treatments before inclusion into the study * suffer from documented selective IgA deficiency with antibodies against IgA * have an acute infection that requires intravenous antibiotic treatment (Last treatment day should be seven days before study entry.) * are known to be infected with HIV, HCV, or HBV * are at high risk of contracting blood-borne viral infections through parenteral drug abuse or life style * suffer from congestive heart failure and receive on-demand treatment with furosemide * show renal dysfunction defined as serum creatinine greater than or equal to 1.5 mg/dL at baseline visit * received another investigational drug in the three weeks preceding study entry * in case of females, are pregnant or nursing mothers